{"gene":"ASCL1","run_date":"2026-04-28T17:12:37","timeline":{"discoveries":[{"year":2016,"finding":"ASCL1 binds distinct genomic loci and regulates mostly distinct genes compared to NEUROD1 in SCLC; ASCL1 targets oncogenic genes including MYCL1, RET, SOX2, NFIB, and multiple NOTCH pathway genes including DLL3, and is required in vivo for tumor formation in mouse models of SCLC.","method":"ChIP-seq, RNA-seq, mouse genetic models (SCLC), shRNA knockdown in human SCLC cell lines","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 — ChIP-seq binding data combined with in vivo mouse genetic requirement, replicated across human and mouse models","pmids":["27452466"],"is_preprint":false},{"year":2017,"finding":"ASCL1 functions as a pioneer transcription factor in glioblastoma stem cells, opening closed chromatin regions to activate a neurogenic gene expression program, promoting terminal neuronal differentiation and suppressing tumorigenicity.","method":"ATAC-seq, ChIP-seq, lentiviral ASCL1 overexpression, Notch inhibition in patient-derived glioblastoma stem cells, in vivo tumor assays","journal":"Cell stem cell","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal chromatin and functional assays in patient-derived cells with in vivo validation","pmids":["28712938"],"is_preprint":false},{"year":2019,"finding":"ASCL1 and Neurogenin2 (Neurog2) induce different neuronal fates by binding largely different genomic sites; divergent binding patterns are determined by enrichment of specific E-box sequences reflecting DNA-binding domain preferences, not prior chromatin state, leading to distinct chromatin accessibility and enhancer activity profiles.","method":"ChIP-seq, ATAC-seq, direct neuronal programming of embryonic stem cells, E-box motif analysis","journal":"Nature neuroscience","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal chromatin profiling methods with mechanistic mutagenesis-level dissection of binding specificity","pmids":["31086315"],"is_preprint":false},{"year":2013,"finding":"FOXO3 shares common genomic targets with ASCL1 in adult neural progenitor cells, co-occupying enhancers of neurogenic pathway genes; FOXO3 inhibits ASCL1-dependent neurogenesis in neural progenitor cells and direct neuronal conversion in fibroblasts, and restrains neurogenesis in vivo.","method":"ChIP-seq (FOXO3 and ASCL1), ATAC-seq/chromatin landscape analysis, loss-of-function in NPCs and fibroblasts, in vivo neurogenesis assays","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 — reciprocal genome-wide occupancy data combined with functional loss-of-function in multiple contexts including in vivo","pmids":["23891001"],"is_preprint":false},{"year":2011,"finding":"ASCL1 (ASH1) transcriptionally activates miR-375 in neuroendocrine lung cancer cells; miR-375 is a downstream effector required for ASH1-mediated induction of neuroendocrine features, and miR-375 directly targets YAP1 to relieve YAP1-mediated growth inhibition.","method":"shRNA knockdown of ASH1, miR-375 overexpression/knockdown, luciferase reporter assays, western blotting in lung cancer cell lines","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2-3 — functional pathway dissection with knockdown and reporter assays in cell lines, single lab","pmids":["21856745"],"is_preprint":false},{"year":2012,"finding":"hASH1 stimulates lung cancer cell migration through a Cdk5/p35 pathway; p35 is a direct transcriptional target of hASH1, and hASH1 expression increases p35/Cdk5 activity to enhance cellular migration.","method":"shRNA knockdown of hASH1, dominant-negative Cdk5 expression, Cdk5 inhibitor roscovitine, hASH1 overexpression in adenocarcinoma cells, ChIP for p35 promoter","journal":"Molecular biology of the cell","confidence":"Medium","confidence_rationale":"Tier 2-3 — direct transcriptional target validation with ChIP and functional phenotypic rescue, single lab","pmids":["22696682"],"is_preprint":false},{"year":2010,"finding":"ASCL1 regulates expression of the CHRNA5/A3/B4 nicotinic acetylcholine receptor gene cluster in small cell lung cancer; ASCL1 knockdown specifically reduced alpha3 and beta4 subunit expression without affecting other nAChR genes, indicating ASCL1-specific transcriptional regulation of this locus.","method":"shRNA knockdown of ASCL1 in SCLC and non-SCLC cell lines, qRT-PCR, in silico promoter analysis for ASCL1 binding sites","journal":"Molecular cancer research","confidence":"Medium","confidence_rationale":"Tier 3 — specific knockdown phenotype with gene expression readout but no direct binding confirmation by ChIP","pmids":["20124469"],"is_preprint":false},{"year":2019,"finding":"In adult mouse neural stem cells, oscillatory Hes1 expression drives cyclic Ascl1 expression to promote active proliferation; high sustained Hes1 expression continuously suppresses Ascl1 and promotes quiescence. Inactivation of Hes1 and related genes upregulates Ascl1 and increases neurogenesis, causing depletion of stem cells, while induction of Ascl1 oscillations activates stem cells.","method":"Genetic inactivation of Hes1 in mouse, live-cell imaging of Hes1/Ascl1 dynamics, conditional Hes1 overexpression, Ascl1 induction in adult mouse brain","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis combined with live-cell dynamics imaging, multiple orthogonal approaches in vivo","pmids":["30862661"],"is_preprint":false},{"year":2021,"finding":"ASCL1 in SCLC cooperates with NKX2-1 and PROX1 to form complexes that co-regulate genes in NOTCH signaling, catecholamine biosynthesis, and cell-cycle processes; ASCL1 is a key dependency factor in SCLC preclinical models and directly regulates multiple essential genes.","method":"ChIP-seq, RNA-seq, super-enhancer mapping, ASCL1 depletion in SCLC models, co-immunoprecipitation","journal":"iScience","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP for complex formation combined with genome-wide binding and transcriptome analysis","pmids":["34466783"],"is_preprint":false},{"year":2013,"finding":"Ascl1/Mash1 promotes oligodendrocyte precursor cell specification from subventricular zone progenitors and regulates the balance between OPC differentiation and proliferation in postnatal cortex; Ascl1 is required for proper remyelination, with remyelinating oligodendrocytes derived from Ascl1+ progenitors.","method":"Conditional genetic deletion of Ascl1 in cortical progenitors or OPCs, mouse focal demyelination model, lineage tracing, immunohistochemistry","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 — conditional KO with defined cellular phenotype and lineage tracing in vivo","pmids":["23739972"],"is_preprint":false},{"year":2022,"finding":"ASCL1 acts as a driver of neuroendocrine/neuronal lineage transcriptional programs in prostate cancer through large-scale chromatin remodeling; ASCL1 motif is enriched in hyper-accessible regions after androgen receptor pathway inhibitor treatment, and targeting ASCL1 switches neuroendocrine lineage back to luminal epithelial state via disruption of PRC2 through UHRF1/AMPK axis.","method":"ATAC-seq, ChIP-seq, ASCL1 knockdown, UHRF1/AMPK pathway inhibition, chromatin architecture analysis in prostate cancer cells","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — multiple chromatin profiling methods with mechanistic pathway dissection and phenotypic reversal","pmids":["35477723"],"is_preprint":false},{"year":2015,"finding":"EZH2 promotes SCLC progression by epigenetically silencing TβRII expression, suppressing TGF-β signaling; ASCL1 is a Smad-dependent TGF-β target gene that promotes survival in SCLC cells, and EZH2 promotes SCLC by suppressing the TGF-β-Smad-ASCL1 pathway.","method":"TβRII overexpression in SCLC cells, EZH2 inhibition, Smad pathway activation, in vitro cell growth and in vivo tumor formation assays","journal":"Cell discovery","confidence":"Medium","confidence_rationale":"Tier 3 — pathway dissection with overexpression/knockdown but ASCL1 role as direct Smad target shown by indirect evidence","pmids":["27462425"],"is_preprint":false},{"year":2014,"finding":"EWS-WT1 fusion oncoprotein directly activates ASCL1 transcription by binding the proximal ASCL1 promoter through multiple WT1-responsive elements, inducing neural gene expression and partial neural differentiation.","method":"Transgenic mouse model, ChIP for EWS-WT1 at ASCL1 promoter, reporter assays with WT1-responsive element mutations, EWS-WT1 siRNA knockdown","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — direct promoter binding confirmed by ChIP with functional rescue, but single lab","pmids":["24934812"],"is_preprint":false},{"year":2021,"finding":"ASCL1 in SCLC represses a SOX9+ mesenchymal/neural crest stem-like state; ASCL1 is critical for expression of NKX2-1, FOXA2, and INSM1 and represses SOX9/RUNX1/RUNX2 program in vivo; genetic depletion of ASCL1 promotes emergence of osteosarcoma and chondroid tumors and inhibits tumor initiation in MYC-driven SCLC.","method":"Genetically engineered mouse models with conditional Ascl1 deletion, RNA-seq, ChIP-seq, tumor histology","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 — in vivo genetic loss-of-function in multiple GEMMs with genome-wide transcriptomic and ChIP analysis","pmids":["34016693"],"is_preprint":false},{"year":2019,"finding":"ASCL1 is a MYCN- and LMO1-dependent member of the adrenergic neuroblastoma core regulatory circuitry; regulatory elements controlling ASCL1 are bound by LMO1, MYCN, GATA3, HAND2, PHOX2B, TBX2 and ISL1; ASCL1 and LMO1 directly regulate CRC gene expression, and ASCL1 is required for neuroblastoma cell growth and arrest of differentiation.","method":"ChIP-seq, RNA-seq, ASCL1 knockdown in neuroblastoma cells, promoter/enhancer analysis","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 — genome-wide ChIP-seq combined with functional knockdown with defined growth and differentiation phenotype","pmids":["31819055"],"is_preprint":false},{"year":2023,"finding":"Endogenous ASCL1 functions both as a classical pioneer factor (binding closed chromatin) and as a non-pioneer remodeler (binding permissive chromatin to induce conformation changes) during human neural differentiation; ASCL1 interacts with BAF SWI/SNF chromatin remodeling complexes, primarily at non-pioneer targets, with codependent DNA binding and remodeling at a subset of ASCL1/SWI/SNF co-targets.","method":"Single-cell RNA-seq, ASCL1 knockout model, ATAC-seq, ChIP-seq, Co-IP for ASCL1-SWI/SNF interaction, chromatin conformation assays","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1-2 — knockout model defining unbound state combined with multiple chromatin assays and validated protein-protein interaction","pmids":["36931659"],"is_preprint":false},{"year":2021,"finding":"Ascl1-mediated astrocyte-to-neuron conversion directly activates 107 target genes; among direct ASCL1 targets, Klf10 regulates neuritogenesis, Myt1 and Myt1l are critical for electrophysiological maturation of induced neurons, and Neurod4 and Chd7 are required for efficient conversion.","method":"RNA-seq, ChIP-seq during astrocyte-to-neuron reprogramming, siRNA knockdown of individual ASCL1 targets, functional electrophysiology assays","journal":"Stem cell reports","confidence":"High","confidence_rationale":"Tier 2 — direct ChIP-seq target identification combined with functional siRNA validation of individual targets with specific phenotypic readouts","pmids":["33577795"],"is_preprint":false},{"year":2018,"finding":"ASCL1 is ubiquitylated on lysines within the bHLH domain in the cytoplasm by the E3 ligase Huwe1, targeting it for degradation; chromatin-bound ASCL1 associates with short ubiquitin chains that do not target it for destruction, occurring on lysines in the N-terminal region or bHLH domain independently of Huwe1. Thus subcellular localization controls the type of ubiquitylation and fate of ASCL1.","method":"Subcellular fractionation, ubiquitin chain immunoprecipitation, lysine-to-arginine mutagenesis, Huwe1 knockdown, proteasome inhibition experiments","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 1-2 — reconstitution-level mutagenesis combined with E3 ligase identification and fractionation, multiple orthogonal methods","pmids":["29545540"],"is_preprint":false},{"year":2022,"finding":"ASCL1 is highly phosphorylated on Serine-Proline sites in GBM stem cells; a phosphorylation-resistant form of ASCL1 (cannot be phosphorylated on SP sites) drives GBM cells more efficiently into neuronal lineage and out of cell cycle than wild-type ASCL1; deletion of ID2 further enhances this differentiation block reversal.","method":"Phospho-ASCL1 immunoblotting, overexpression of phospho-mutant ASCL1 in GBM stem cells, CRISPR deletion of ID2, cell cycle analysis, differentiation markers","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 — mutagenesis of phosphorylation sites with functional differentiation/proliferation readout, single lab","pmids":["35149717"],"is_preprint":false},{"year":2020,"finding":"Injury-induced STAT signaling limits Ascl1-mediated reprogramming of Müller glia into retinal neurons; STAT signaling directs Ascl1 to developmentally inappropriate chromatin targets; pharmacological STAT inhibition combined with Ascl1 expression dramatically increases neuronal generation from Müller glia.","method":"Single-cell RNA-seq, Ascl1-ChIPseq, ATAC-seq in Müller glia, STAT inhibitor treatment, transgenic Ascl1 expression","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 — ChIP-seq demonstrating STAT-dependent target shifting of ASCL1 with functional consequence, multiple orthogonal methods","pmids":["32075759"],"is_preprint":false},{"year":2020,"finding":"ASCL1 regulates neurodevelopmental transcription factors and cell cycle genes in GBM; genetic loss of ASCL1 significantly reduces glioma cell proliferation in a mouse glioma model, with RNA-seq revealing downregulation of cell cycle genes upon ASCL1 loss.","method":"RNA-seq, conditional Ascl1 deletion in mouse glioma model, survival analysis, cell proliferation assays","journal":"Glia","confidence":"Medium","confidence_rationale":"Tier 2 — genetic KO in vivo with transcriptome analysis, but limited mechanistic depth beyond transcriptional targets","pmids":["32573857"],"is_preprint":false},{"year":2018,"finding":"ASCL1 proneural transcription factor governs glioblastoma stem cell proneural subgroup affiliation by directly repressing NDRG1 (a mesenchymal gene); ASCL1 binding to NDRG1 regulatory regions drives a glial-to-neuronal lineage switch while concomitantly suppressing mesenchymal features.","method":"ChIP-seq, ASCL1 overexpression/knockdown, NDRG1 silencing, tumor formation assays, gene expression profiling in patient-derived GSCs","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 2-3 — ChIP-seq with functional validation by knockdown, single lab","pmids":["30538287"],"is_preprint":false},{"year":2024,"finding":"ASCL1 is required for the neuroendocrine lineage transition in prostate cancer; ASCL1+ cells arise from KRT8+ luminal cells in vivo; Ascl1 loss in established NEPC causes transient regression followed by recurrence, but deletion before transplantation abrogates lineage plasticity resulting in castration-sensitive adenocarcinomas.","method":"Mouse prostate organoid transplantation model, multiplexed immunofluorescence, spatial transcriptomics, genetic Ascl1 deletion at different tumor stages","journal":"Nature cancer","confidence":"High","confidence_rationale":"Tier 2 — in vivo genetic model with spatial multi-omics and staged deletion showing temporal dependency","pmids":["39394434"],"is_preprint":false},{"year":2024,"finding":"Ascl1 loss in mouse prostate cancer model does not decrease tumor incidence or growth, but causes notable decrease in neuroendocrine identity and increase in basal-like identity, establishing ASCL1 as required for driving NE differentiation but not overall tumor growth in this context.","method":"Prostate organoid allografts from Rb1/Trp53/Myc GEMMs, conditional Ascl1 genetic deletion, IHC/RNA-seq for lineage markers","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — clean in vivo KO with specific lineage phenotype, single lab","pmids":["39264686"],"is_preprint":false},{"year":2020,"finding":"Gsx2 physically interacts with the bHLH domain of Ascl1 in lateral ganglionic eminence progenitors, interfering with Ascl1's DNA binding and limiting neurogenesis; this Gsx2-Ascl1 interaction is enriched in LGE ventricular zone progenitors, while Ascl1-E-protein (Tcf3) interactions predominate in the subventricular zone.","method":"Luciferase/reporter assays, co-immunoprecipitation, DNA-binding assays, proximity ligation assay in tissue sections, conditional misexpression in mouse","journal":"Development","confidence":"High","confidence_rationale":"Tier 1-2 — direct physical interaction validated by co-IP and DNA-binding assays, spatial proximity ligation in tissue with functional luciferase readout","pmids":["32122989"],"is_preprint":false},{"year":2022,"finding":"ASCL1 in SCLC regulates super-enhancer-associated miRNAs including miR-7, miR-375, miR-200b-3p, and miR-429 (activating them) and suppresses miR-455-3p; multiple ASCL1-regulated miRNAs combinatorially repress targets including YAP1 (co-targeted by miR-9 and miR-375).","method":"CUT&Tag chromatin profiling (H3K27me3, H3K4me3, H3K27ac), ASCL1 knockdown with RNA-seq and miRNA array in SCLC cells","journal":"Cancer science","confidence":"Medium","confidence_rationale":"Tier 2-3 — genome-wide chromatin and transcriptome profiling after ASCL1 depletion, single lab","pmids":["35789143"],"is_preprint":false},{"year":2021,"finding":"The BAP1/ASXL3/BRD4 epigenetic axis regulates ASCL1-dependent SCLC transcriptional programming; pharmacological inhibition of BAP1 catalytic activity induces ASXL3 degradation, disrupting the BAP1/ASXL3/BRD4 complex at active enhancers and repressing ASCL1/MYCL/E2F neuroendocrine lineage signaling.","method":"BAP1 inhibitor (iBAP-II) treatment, Co-IP for BAP1/ASXL3/BRD4 complex, ChIP-seq at enhancers, cell viability and in vivo tumor assays","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2-3 — complex shown by Co-IP with chromatin evidence and functional readout, but epigenetic regulation of ASCL1 shown pharmacologically","pmids":["35194152"],"is_preprint":false},{"year":2000,"finding":"Notch1 intracellular domain inhibits differentiation of neuroblastoma cells; HES1 binds to an N-box sequence in the HASH-1 (ASCL1) promoter in gel mobility shift assays, and HES1 activation during differentiation contributes to HASH-1 downregulation.","method":"Gel mobility shift assay with HES1 protein and ASCL1 N-box oligonucleotide, constitutive Notch1-ICD expression, differentiation assays in neuroblastoma cell lines","journal":"International journal of cancer","confidence":"Medium","confidence_rationale":"Tier 3 — direct binding of HES1 to ASCL1 promoter element confirmed by EMSA, with functional differentiation phenotype","pmids":["11054669"],"is_preprint":false},{"year":2018,"finding":"ASCL1 conditional deletion in NG2-glia of embryonic or adult spinal cord results in significant reduction in proliferation but not differentiation of these cells; WM NG2-glia maintain higher ASCL1 levels than GM NG2-glia, correlating with higher proliferative capacity; ASCL1+ OLP clones are primarily restricted to GM or WM compartments.","method":"Conditional Ascl1 deletion in NG2-glia, long-term clonal lineage analysis, BrdU/EdU proliferation assays in spinal cord","journal":"Glia","confidence":"Medium","confidence_rationale":"Tier 2 — conditional KO with specific cellular proliferation phenotype distinguished from differentiation, in vivo","pmids":["29683222"],"is_preprint":false},{"year":2022,"finding":"In neuroblastoma, ASCL1 maintains rapid proliferation and regulates chromatin accessibility at differentiation gene regulatory regions; ASCL1 deletion compromises the ability of MYC/MYCN and CRC component proteins PHOX2B and GATA3 to bind chromatin, without substantially affecting CRC gene transcript levels.","method":"CRISPR deletion of ASCL1 in neuroblastoma cell lines, genome-wide RNA-seq, ATAC-seq, ChIP-seq for PHOX2B/GATA3 binding, proliferation assays","journal":"Frontiers in cell and developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal genomic methods with CRISPR KO, single lab","pmids":["36263020"],"is_preprint":false},{"year":2022,"finding":"Ascl1, together with Mef2c, drives efficient cardiac reprogramming; MEF2C shifts ASCL1 chromatin binding away from neuronal gene targets toward cardiac gene targets, demonstrating cross-lineage pioneer factor activity dependent on partner transcription factor context.","method":"ChIP-seq, RNA-seq during cardiac reprogramming, MEF2C co-expression with ASCL1, comparison to neuronal reprogramming regulatome","journal":"Cell stem cell","confidence":"Medium","confidence_rationale":"Tier 2 — genome-wide binding shift shown by ChIP-seq with functional cardiac reprogramming outcome, single lab","pmids":["36206732"],"is_preprint":false},{"year":2013,"finding":"Loss of Ascl1 in mouse dorsal horn specifically eliminates late-born inhibitory interneurons; Ascl1-dependent inhibitory interneurons expressing pDyn, Kcnip2, and Rorb are key players in nociceptive reflex plasticity.","method":"Genome-wide expression profiling of Ascl1-/- spinal dorsal horn, in situ hybridization, isolated spinal cord electrophysiology for nociceptive reflex","journal":"The Journal of neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 — genetic KO with defined neuronal population loss and functional electrophysiology","pmids":["23616538"],"is_preprint":false},{"year":2024,"finding":"ASCL1 drives drug tolerance to osimertinib in EGFR-mutant lung cancer by initiating an epithelial-to-mesenchymal gene expression program in permissive cellular contexts.","method":"Patient-derived xenograft osimertinib treatment, single-cell transcriptional profiling of residual disease, ASCL1 expression analysis","journal":"Cancer research","confidence":"Low","confidence_rationale":"Tier 3 — transcriptional profiling with mechanistic inference, limited functional validation of ASCL1 as causative driver","pmids":["38359163"],"is_preprint":false}],"current_model":"ASCL1 is a bHLH proneural transcription factor and pioneer factor that binds specific E-box sequences to open closed chromatin and activate neurogenic/neuroendocrine gene expression programs; it cooperates with chromatin remodeling complexes (BAF/SWI/SNF) and partner transcription factors (NKX2-1, PROX1, MEF2C) to regulate distinct genomic targets, and its activity is modulated post-translationally by phosphorylation on SP sites (which promotes proliferation over differentiation) and by context-dependent ubiquitylation through Huwe1 (cytoplasmic, leading to degradation) or short non-degradative ubiquitin chains on chromatin; in neural and neuroendocrine development it acts downstream of Notch/Hes1 repression and upstream of multiple lineage-specifying targets including miRNAs, driving both progenitor proliferation and differentiation in a dose/oscillation-dependent manner, while also being required for neuroendocrine lineage identity in lung and prostate cancers."},"narrative":{"teleology":[{"year":2000,"claim":"Establishing that ASCL1 transcription is directly repressed by HES1 through N-box binding placed ASCL1 downstream of Notch signaling, answering how Notch activation suppresses neuronal differentiation at the promoter level.","evidence":"EMSA showing HES1 binding to ASCL1 promoter N-box, Notch1-ICD overexpression in neuroblastoma cells","pmids":["11054669"],"confidence":"Medium","gaps":["No ChIP confirmation of HES1 occupancy at endogenous ASCL1 promoter in vivo","Kinetics of HES1-mediated repression not resolved"]},{"year":2011,"claim":"Identification of miR-375 as a direct ASCL1 transcriptional target that represses YAP1 revealed a non-coding RNA effector arm through which ASCL1 promotes neuroendocrine features in lung cancer.","evidence":"shRNA knockdown of ASCL1, miR-375 manipulation, luciferase reporter assays in NE lung cancer lines","pmids":["21856745"],"confidence":"Medium","gaps":["Direct ASCL1 binding to miR-375 regulatory region not shown by ChIP at this stage","Contribution of miR-375 relative to other ASCL1 targets unclear"]},{"year":2013,"claim":"Conditional deletion studies demonstrated that ASCL1 is required not only for neuronal specification (inhibitory dorsal horn interneurons) but also for oligodendrocyte precursor cell specification and remyelination, broadening its known lineage roles beyond neurons.","evidence":"Conditional Ascl1 KO in cortical/OPC progenitors and spinal dorsal horn, lineage tracing, demyelination model","pmids":["23739972","23616538"],"confidence":"High","gaps":["Direct transcriptional targets mediating OPC vs. neuronal specification not distinguished","Whether ASCL1 binding sites differ in OPC vs. neuronal progenitors was unknown"]},{"year":2013,"claim":"Demonstration that FOXO3 co-occupies ASCL1-bound enhancers and antagonizes ASCL1-dependent neurogenesis established a paradigm for how signaling pathways modulate ASCL1 pioneer activity through co-factor competition at shared genomic targets.","evidence":"ChIP-seq for FOXO3 and ASCL1 in neural progenitor cells, loss-of-function in NPCs/fibroblasts, in vivo neurogenesis","pmids":["23891001"],"confidence":"High","gaps":["Molecular mechanism of FOXO3 antagonism (competition vs. active repression) not resolved","Whether FOXO3 blocks ASCL1 chromatin opening specifically was untested"]},{"year":2016,"claim":"Genome-wide ChIP-seq in SCLC revealed that ASCL1 and NEUROD1 define distinct transcriptional subgroups by binding largely non-overlapping genomic sites, establishing ASCL1 as a master regulator of a specific SCLC oncogenic program including MYCL1, RET, and DLL3.","evidence":"ChIP-seq and RNA-seq in human SCLC lines, shRNA knockdown, mouse SCLC GEMMs","pmids":["27452466"],"confidence":"High","gaps":["How ASCL1 vs. NEUROD1 binding specificity is determined at the DNA/protein level was unknown","Whether ASCL1 acts as a pioneer factor in SCLC was not yet addressed"]},{"year":2017,"claim":"ATAC-seq and ChIP-seq in glioblastoma stem cells provided the first direct evidence that ASCL1 functions as a pioneer factor, opening previously closed chromatin to activate a neurogenic differentiation program and suppress tumorigenicity.","evidence":"ATAC-seq/ChIP-seq after lentiviral ASCL1 expression in patient-derived GBM stem cells, in vivo tumor assays","pmids":["28712938"],"confidence":"High","gaps":["Whether pioneer activity requires cofactors or is intrinsic to ASCL1 was not dissected","Mechanism of chromatin opening (nucleosome displacement vs. remodeler recruitment) unresolved"]},{"year":2018,"claim":"Biochemical dissection of ASCL1 ubiquitylation revealed that subcellular location dictates its post-translational fate: cytoplasmic Huwe1-mediated ubiquitylation on bHLH-domain lysines drives degradation, while chromatin-bound ASCL1 carries short non-degradative ubiquitin chains on distinct residues.","evidence":"Subcellular fractionation, ubiquitin IP, lysine-to-arginine mutagenesis, Huwe1 knockdown","pmids":["29545540"],"confidence":"High","gaps":["Function of non-degradative chromatin-associated ubiquitin chains unknown","E3 ligase responsible for chromatin-associated ubiquitylation not identified"]},{"year":2019,"claim":"Comparison of ASCL1 and Neurog2 binding in ES cell-derived neurons showed that divergent neuronal fates arise from intrinsic E-box sequence preferences of the bHLH DNA-binding domains rather than from prior chromatin states, resolving how two pioneer factors accessing closed chromatin produce distinct outcomes.","evidence":"ChIP-seq, ATAC-seq, E-box motif analysis during directed neuronal programming from ESCs","pmids":["31086315"],"confidence":"High","gaps":["Structural basis for differential E-box recognition not determined","Whether cofactor interactions modulate E-box selectivity in vivo untested"]},{"year":2019,"claim":"Live imaging of Hes1/Ascl1 oscillatory dynamics in adult neural stem cells demonstrated that oscillatory (low-amplitude) Ascl1 expression maintains proliferative capacity while sustained high expression drives differentiation, establishing expression dynamics as a functional switch.","evidence":"Live-cell imaging, conditional Hes1 genetic manipulation, Ascl1 induction in adult mouse brain","pmids":["30862661"],"confidence":"High","gaps":["How oscillatory vs. sustained ASCL1 protein levels differentially engage target genes mechanistically was unresolved","Post-translational regulation during oscillations not examined"]},{"year":2020,"claim":"STAT signaling in injured Müller glia was shown to redirect Ascl1 binding to developmentally inappropriate chromatin targets, establishing that the signaling environment can reprogram pioneer factor genomic occupancy and limit regenerative neurogenesis.","evidence":"Ascl1 ChIP-seq ± STAT inhibition in Müller glia, single-cell RNA-seq, ATAC-seq","pmids":["32075759"],"confidence":"High","gaps":["Whether STAT factors physically interact with ASCL1 or act indirectly via chromatin remodeling unknown","Generalizability to other injury contexts not tested"]},{"year":2021,"claim":"Identification of ASCL1 cooperation with NKX2-1 and PROX1 as co-occupying transcription factors at super-enhancers in SCLC, combined with in vivo demonstration that ASCL1 loss derepresses a SOX9+ mesenchymal program while being required for NE identity, defined ASCL1 as both an activator of NE lineage and a repressor of alternative fates.","evidence":"ChIP-seq, Co-IP for ASCL1/NKX2-1/PROX1, conditional Ascl1 deletion in SCLC GEMMs, RNA-seq","pmids":["34466783","34016693"],"confidence":"High","gaps":["Stoichiometry and assembly order of ASCL1/NKX2-1/PROX1 complex unknown","Whether ASCL1 actively recruits repressive machinery to SOX9 loci or acts indirectly unclear"]},{"year":2022,"claim":"ASCL1 was established as a driver of neuroendocrine lineage plasticity in prostate cancer through chromatin remodeling involving a PRC2/UHRF1/AMPK axis, and partner-dependent redirection of ASCL1 binding by MEF2C toward cardiac genes demonstrated that ASCL1 pioneer activity is fundamentally context-dependent.","evidence":"ATAC-seq/ChIP-seq in prostate cancer with ASCL1 knockdown and UHRF1/AMPK pathway perturbation; ChIP-seq during ASCL1+MEF2C cardiac reprogramming","pmids":["35477723","36206732"],"confidence":"High","gaps":["Direct physical interaction between ASCL1 and PRC2 components not shown","How MEF2C mechanistically redirects ASCL1 DNA binding unclear"]},{"year":2023,"claim":"Endogenous ASCL1 knockout during human neural differentiation combined with SWI/SNF interaction studies revealed a dual mode: classical pioneer activity at closed chromatin and non-pioneer remodeling at permissive chromatin via BAF complex recruitment, resolving how ASCL1 engages chromatin through two mechanistically distinct pathways.","evidence":"ASCL1 KO hESC differentiation model, ATAC-seq, ChIP-seq, Co-IP for ASCL1-SWI/SNF","pmids":["36931659"],"confidence":"High","gaps":["Which BAF complex subunits directly contact ASCL1 not mapped","Whether pioneer vs. non-pioneer mode distinction applies in cancer contexts unknown"]},{"year":2024,"claim":"Staged genetic deletion in prostate cancer models showed ASCL1 is required for initiating the neuroendocrine lineage transition from luminal cells but becomes partially dispensable in established tumors, revealing a temporal hierarchy in ASCL1 dependency for lineage plasticity.","evidence":"Mouse organoid transplantation with conditional Ascl1 deletion at different stages, spatial transcriptomics, multiplexed IF","pmids":["39394434","39264686"],"confidence":"High","gaps":["Compensatory factors maintaining NE identity after ASCL1 loss in established tumors not identified","Whether ASCL1 re-expression drives re-emergence of NE phenotype untested"]},{"year":null,"claim":"Key unresolved questions include the structural basis for ASCL1's differential E-box selectivity, the identity and function of the E3 ligase responsible for non-degradative chromatin-associated ubiquitylation, and how oscillatory vs. sustained ASCL1 expression differentially engages downstream targets at the molecular level.","evidence":"","pmids":[],"confidence":"Low","gaps":["No structural model of ASCL1 DNA-binding domain bound to preferred E-box variants","E3 ligase for chromatin-associated non-degradative ubiquitylation unknown","Molecular mechanism linking ASCL1 protein oscillation amplitude to target gene selection unresolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,1,2,3,15,16,24]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,1,4,8,10,13,14,16,25]},{"term_id":"GO:0042393","term_label":"histone binding","supporting_discovery_ids":[15]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,1,2,15,17]},{"term_id":"GO:0005694","term_label":"chromosome","supporting_discovery_ids":[15,17]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[17]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,1,2,4,8,10,13,14,15,16,25]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[1,2,10,15,29]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[7,9,19,24,31]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[7,11,27]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[8,18,20,29]}],"complexes":["BAF/SWI-SNF complex"],"partners":["NKX2-1","PROX1","MEF2C","HUWE1","GSX2","FOXO3","HES1","TCF3"],"other_free_text":[]},"mechanistic_narrative":"ASCL1 is a basic helix-loop-helix (bHLH) proneural transcription factor that functions as a pioneer factor, binding specific E-box sequences to open closed chromatin and activate neuronal and neuroendocrine gene expression programs across diverse cellular contexts [PMID:28712938, PMID:31086315, PMID:36931659]. ASCL1 cooperates with BAF/SWI-SNF chromatin remodeling complexes at permissive chromatin sites and with lineage-specifying partner transcription factors—including NKX2-1/PROX1 in small cell lung cancer, PHOX2B/GATA3 in neuroblastoma, and MEF2C in cardiac reprogramming—that redirect its genomic binding from neuronal to alternative lineage targets [PMID:36931659, PMID:34466783, PMID:36263020, PMID:36206732]. Its activity is tuned by oscillatory expression dynamics downstream of Notch/Hes1 signaling, by serine-proline phosphorylation that favors proliferation over differentiation, and by subcellular-compartment-specific ubiquitylation wherein cytoplasmic Huwe1-mediated ubiquitylation drives degradation while chromatin-associated short ubiquitin chains preserve ASCL1 function [PMID:30862661, PMID:35149717, PMID:29545540]. ASCL1 is required for neuroendocrine lineage identity and tumor initiation in small cell lung cancer and neuroendocrine prostate cancer, where its loss abolishes neuroendocrine differentiation and shifts cells toward alternative lineage states [PMID:27452466, PMID:39394434, PMID:34016693]."},"prefetch_data":{"uniprot":{"accession":"P50553","full_name":"Achaete-scute homolog 1","aliases":["Class A basic helix-loop-helix protein 46","bHLHa46"],"length_aa":236,"mass_kda":25.5,"function":"Transcription factor that plays a key role in neuronal differentiation: acts as a pioneer transcription factor, accessing closed chromatin to allow other factors to bind and activate neural pathways. Directly binds the E box motif (5'-CANNTG-3') on promoters and promotes transcription of neuronal genes. The combination of three transcription factors, ASCL1, POU3F2/BRN2 and MYT1L, is sufficient to reprogram fibroblasts and other somatic cells into induced neuronal (iN) cells in vitro. Plays a role at early stages of development of specific neural lineages in most regions of the CNS, and of several lineages in the PNS. Essential for the generation of olfactory and autonomic neurons. Acts synergistically with FOXN4 to specify the identity of V2b neurons rather than V2a from bipotential p2 progenitors during spinal cord neurogenesis, probably through DLL4-NOTCH signaling activation. Involved in the regulation of neuroendocrine cell development in the glandular stomach (By similarity)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/P50553/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ASCL1","classification":"Not Classified","n_dependent_lines":30,"n_total_lines":1208,"dependency_fraction":0.024834437086092714},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ASCL1","total_profiled":1310},"omim":[{"mim_id":"621003","title":"TRANSCRIPTION FACTOR Sp9; SP9","url":"https://www.omim.org/entry/621003"},{"mim_id":"618646","title":"DIENCEPHALIC-MESENCEPHALIC JUNCTION DYSPLASIA SYNDROME 2; DMJDS2","url":"https://www.omim.org/entry/618646"},{"mim_id":"617578","title":"FER3-LIKE bHLH TRANSCRIPTION FACTOR; FERD3L","url":"https://www.omim.org/entry/617578"},{"mim_id":"617546","title":"HELT bHLH TRANSCRIPTION FACTOR; HELT","url":"https://www.omim.org/entry/617546"},{"mim_id":"616741","title":"PR DOMAIN-CONTAINING PROTEIN 13; PRDM13","url":"https://www.omim.org/entry/616741"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"brain","ntpm":15.5},{"tissue":"liver","ntpm":10.4},{"tissue":"pituitary gland","ntpm":28.2}],"url":"https://www.proteinatlas.org/search/ASCL1"},"hgnc":{"alias_symbol":["ASH1","HASH1","bHLHa46"],"prev_symbol":[]},"alphafold":{"accession":"P50553","domains":[{"cath_id":"4.10.280.10","chopping":"118-188","consensus_level":"medium","plddt":94.6341,"start":118,"end":188}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P50553","model_url":"https://alphafold.ebi.ac.uk/files/AF-P50553-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P50553-F1-predicted_aligned_error_v6.png","plddt_mean":67.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ASCL1","jax_strain_url":"https://www.jax.org/strain/search?query=ASCL1"},"sequence":{"accession":"P50553","fasta_url":"https://rest.uniprot.org/uniprotkb/P50553.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P50553/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P50553"}},"corpus_meta":[{"pmid":"9809065","id":"PMC_9809065","title":"Localization of ASH1 mRNA particles in living yeast.","date":"1998","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/9809065","citation_count":1312,"is_preprint":false},{"pmid":"33011388","id":"PMC_33011388","title":"SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization.","date":"2020","source":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33011388","citation_count":414,"is_preprint":false},{"pmid":"27452466","id":"PMC_27452466","title":"ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs.","date":"2016","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/27452466","citation_count":412,"is_preprint":false},{"pmid":"9735357","id":"PMC_9735357","title":"The Drosophila trithorax group proteins BRM, ASH1 and ASH2 are subunits of distinct protein complexes.","date":"1998","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/9735357","citation_count":239,"is_preprint":false},{"pmid":"12397363","id":"PMC_12397363","title":"Histone methylation by the Drosophila epigenetic transcriptional regulator Ash1.","date":"2002","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/12397363","citation_count":229,"is_preprint":false},{"pmid":"15031712","id":"PMC_15031712","title":"The histone methyltransferases Trithorax and Ash1 prevent transcriptional silencing by Polycomb group proteins.","date":"2004","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/15031712","citation_count":207,"is_preprint":false},{"pmid":"16497925","id":"PMC_16497925","title":"RETRACTED: Noncoding RNAs of trithorax response elements recruit Drosophila Ash1 to Ultrabithorax.","date":"2006","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/16497925","citation_count":177,"is_preprint":false},{"pmid":"10792032","id":"PMC_10792032","title":"The myosin motor, Myo4p, binds Ash1 mRNA via the adapter protein, She3p.","date":"2000","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10792032","citation_count":176,"is_preprint":false},{"pmid":"11032818","id":"PMC_11032818","title":"She2p, a novel RNA-binding protein tethers ASH1 mRNA to the Myo4p myosin motor via She3p.","date":"2000","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/11032818","citation_count":168,"is_preprint":false},{"pmid":"10209102","id":"PMC_10209102","title":"Structural elements required for the localization of ASH1 mRNA and of a green fluorescent protein reporter particle in vivo.","date":"1999","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/10209102","citation_count":165,"is_preprint":false},{"pmid":"11101531","id":"PMC_11101531","title":"She2p is a novel RNA-binding protein that recruits the Myo4p-She3p complex to ASH1 mRNA.","date":"2000","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/11101531","citation_count":164,"is_preprint":false},{"pmid":"15198983","id":"PMC_15198983","title":"A new yeast PUF family protein, Puf6p, represses ASH1 mRNA translation and is required for its localization.","date":"2004","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/15198983","citation_count":151,"is_preprint":false},{"pmid":"28712938","id":"PMC_28712938","title":"ASCL1 Reorganizes Chromatin to Direct Neuronal Fate and Suppress Tumorigenicity of Glioblastoma Stem Cells.","date":"2017","source":"Cell stem cell","url":"https://pubmed.ncbi.nlm.nih.gov/28712938","citation_count":142,"is_preprint":false},{"pmid":"17544230","id":"PMC_17544230","title":"Trithorax-group protein ASH1 methylates histone H3 lysine 36.","date":"2007","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/17544230","citation_count":130,"is_preprint":false},{"pmid":"30862661","id":"PMC_30862661","title":"High Hes1 expression and resultant Ascl1 suppression regulate quiescent vs. active neural stem cells in the adult mouse brain.","date":"2019","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/30862661","citation_count":130,"is_preprint":false},{"pmid":"23891001","id":"PMC_23891001","title":"FOXO3 shares common targets with ASCL1 genome-wide and inhibits ASCL1-dependent neurogenesis.","date":"2013","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/23891001","citation_count":126,"is_preprint":false},{"pmid":"21856745","id":"PMC_21856745","title":"miR-375 is activated by ASH1 and inhibits YAP1 in a lineage-dependent manner in lung cancer.","date":"2011","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/21856745","citation_count":123,"is_preprint":false},{"pmid":"35477723","id":"PMC_35477723","title":"ASCL1 activates neuronal stem cell-like lineage programming through remodeling of the chromatin landscape in prostate cancer.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35477723","citation_count":117,"is_preprint":false},{"pmid":"23739972","id":"PMC_23739972","title":"Ascl1/Mash1 promotes brain oligodendrogenesis during myelination and remyelination.","date":"2013","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/23739972","citation_count":116,"is_preprint":false},{"pmid":"16314178","id":"PMC_16314178","title":"Stable incorporation of sequence specific repressors Ash1 and Ume6 into the Rpd3L complex.","date":"2005","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/16314178","citation_count":115,"is_preprint":false},{"pmid":"8725238","id":"PMC_8725238","title":"The Drosophila ash1 gene product, which is localized at specific sites on polytene chromosomes, contains a SET domain and a PHD finger.","date":"1996","source":"Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8725238","citation_count":114,"is_preprint":false},{"pmid":"22488473","id":"PMC_22488473","title":"Histone methyltransferase ASH1 orchestrates fibrogenic gene transcription during myofibroblast transdifferentiation.","date":"2012","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/22488473","citation_count":108,"is_preprint":false},{"pmid":"17588515","id":"PMC_17588515","title":"Local activation of yeast ASH1 mRNA translation through phosphorylation of Khd1p by the casein kinase Yck1p.","date":"2007","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/17588515","citation_count":100,"is_preprint":false},{"pmid":"16103883","id":"PMC_16103883","title":"Upregulation of ASCL1 and inhibition of Notch signaling pathway characterize progressive astrocytoma.","date":"2005","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16103883","citation_count":99,"is_preprint":false},{"pmid":"31086315","id":"PMC_31086315","title":"Proneural factors Ascl1 and Neurog2 contribute to neuronal subtype identities by establishing distinct chromatin landscapes.","date":"2019","source":"Nature neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/31086315","citation_count":99,"is_preprint":false},{"pmid":"27462425","id":"PMC_27462425","title":"EZH2 promotes progression of small cell lung cancer by suppressing the TGF-β-Smad-ASCL1 pathway.","date":"2015","source":"Cell discovery","url":"https://pubmed.ncbi.nlm.nih.gov/27462425","citation_count":95,"is_preprint":false},{"pmid":"19915673","id":"PMC_19915673","title":"The ASH1 HOMOLOG 2 (ASHH2) histone H3 methyltransferase is required for ovule and anther development in Arabidopsis.","date":"2009","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/19915673","citation_count":94,"is_preprint":false},{"pmid":"32075759","id":"PMC_32075759","title":"STAT Signaling Modifies Ascl1 Chromatin Binding and Limits Neural Regeneration from Muller Glia in Adult Mouse Retina.","date":"2020","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/32075759","citation_count":91,"is_preprint":false},{"pmid":"11867544","id":"PMC_11867544","title":"The Khd1 protein, which has three KH RNA-binding motifs, is required for proper localization of ASH1 mRNA in yeast.","date":"2002","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/11867544","citation_count":88,"is_preprint":false},{"pmid":"18413716","id":"PMC_18413716","title":"Translation of ASH1 mRNA is repressed by Puf6p-Fun12p/eIF5B interaction and released by CK2 phosphorylation.","date":"2008","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/18413716","citation_count":87,"is_preprint":false},{"pmid":"14657947","id":"PMC_14657947","title":"hASH1 expression is closely correlated with endocrine phenotype and differentiation extent in pulmonary neuroendocrine tumors.","date":"2004","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/14657947","citation_count":81,"is_preprint":false},{"pmid":"24004944","id":"PMC_24004944","title":"The trithorax group proteins Kismet and ASH1 promote H3K36 dimethylation to counteract Polycomb group repression in Drosophila.","date":"2013","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/24004944","citation_count":73,"is_preprint":false},{"pmid":"31819055","id":"PMC_31819055","title":"ASCL1 is a MYCN- and LMO1-dependent member of the adrenergic neuroblastoma core regulatory circuitry.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31819055","citation_count":72,"is_preprint":false},{"pmid":"22696682","id":"PMC_22696682","title":"Achaete-scute homologue-1 (ASH1) stimulates migration of lung cancer cells through Cdk5/p35 pathway.","date":"2012","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/22696682","citation_count":70,"is_preprint":false},{"pmid":"25520623","id":"PMC_25520623","title":"Transcriptional control of vertebrate neurogenesis by the proneural factor Ascl1.","date":"2014","source":"Frontiers in cellular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/25520623","citation_count":67,"is_preprint":false},{"pmid":"11094082","id":"PMC_11094082","title":"Functional interaction between the coactivator Drosophila CREB-binding protein and ASH1, a member of the trithorax group of chromatin modifiers.","date":"2000","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11094082","citation_count":63,"is_preprint":false},{"pmid":"34016693","id":"PMC_34016693","title":"ASCL1 represses a SOX9+ neural crest stem-like state in small cell lung cancer.","date":"2021","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/34016693","citation_count":62,"is_preprint":false},{"pmid":"10454589","id":"PMC_10454589","title":"Trithorax and ASH1 interact directly and associate with the trithorax group-responsive bxd region of the Ultrabithorax promoter.","date":"1999","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10454589","citation_count":59,"is_preprint":false},{"pmid":"19244342","id":"PMC_19244342","title":"Nuclear shuttling of She2p couples ASH1 mRNA localization to its translational repression by recruiting Loc1p and Puf6p.","date":"2009","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/19244342","citation_count":59,"is_preprint":false},{"pmid":"9566907","id":"PMC_9566907","title":"Ash1, a daughter cell-specific protein, is required for pseudohyphal growth of Saccharomyces cerevisiae.","date":"1998","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9566907","citation_count":56,"is_preprint":false},{"pmid":"15459746","id":"PMC_15459746","title":"Daughter-specific repression of Saccharomyces cerevisiae HO: Ash1 is the commander.","date":"2004","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/15459746","citation_count":55,"is_preprint":false},{"pmid":"26732729","id":"PMC_26732729","title":"miR-124-9-9* potentiates Ascl1-induced reprogramming of cultured Müller glia.","date":"2016","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/26732729","citation_count":54,"is_preprint":false},{"pmid":"30468429","id":"PMC_30468429","title":"ASH1-catalyzed H3K36 methylation drives gene repression and marks H3K27me2/3-competent chromatin.","date":"2018","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/30468429","citation_count":53,"is_preprint":false},{"pmid":"11054669","id":"PMC_11054669","title":"Induced neuroblastoma cell differentiation, associated with transient HES-1 activity and reduced HASH-1 expression, is inhibited by Notch1.","date":"2000","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/11054669","citation_count":50,"is_preprint":false},{"pmid":"7982557","id":"PMC_7982557","title":"Molecular genetic analysis of the Drosophila melanogaster gene absent, small or homeotic discs1 (ash1).","date":"1994","source":"Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/7982557","citation_count":48,"is_preprint":false},{"pmid":"31068386","id":"PMC_31068386","title":"Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702).","date":"2019","source":"The oncologist","url":"https://pubmed.ncbi.nlm.nih.gov/31068386","citation_count":48,"is_preprint":false},{"pmid":"30538287","id":"PMC_30538287","title":"The proneural gene ASCL1 governs the transcriptional subgroup affiliation in glioblastoma stem cells by directly repressing the mesenchymal gene NDRG1.","date":"2018","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/30538287","citation_count":48,"is_preprint":false},{"pmid":"34466783","id":"PMC_34466783","title":"ASCL1, NKX2-1, and PROX1 co-regulate subtype-specific genes in small-cell lung cancer.","date":"2021","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/34466783","citation_count":47,"is_preprint":false},{"pmid":"18566598","id":"PMC_18566598","title":"Nuclear transit of the RNA-binding protein She2 is required for translational control of localized ASH1 mRNA.","date":"2008","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/18566598","citation_count":46,"is_preprint":false},{"pmid":"29158494","id":"PMC_29158494","title":"Mrg15 stimulates Ash1 H3K36 methyltransferase activity and facilitates Ash1 Trithorax group protein function in Drosophila.","date":"2017","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/29158494","citation_count":46,"is_preprint":false},{"pmid":"39394434","id":"PMC_39394434","title":"The neuroendocrine transition in prostate cancer is dynamic and dependent on ASCL1.","date":"2024","source":"Nature cancer","url":"https://pubmed.ncbi.nlm.nih.gov/39394434","citation_count":44,"is_preprint":false},{"pmid":"24037524","id":"PMC_24037524","title":"ASCL1 and RET expression defines a clinically relevant subgroup of lung adenocarcinoma characterized by neuroendocrine differentiation.","date":"2013","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/24037524","citation_count":43,"is_preprint":false},{"pmid":"28181538","id":"PMC_28181538","title":"Epigenetic Editing of Ascl1 Gene in Neural Stem Cells by Optogenetics.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28181538","citation_count":43,"is_preprint":false},{"pmid":"36931659","id":"PMC_36931659","title":"Pioneer factor ASCL1 cooperates with the mSWI/SNF complex at distal regulatory elements to regulate human neural differentiation.","date":"2023","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/36931659","citation_count":42,"is_preprint":false},{"pmid":"23616538","id":"PMC_23616538","title":"Genome-wide expression analysis of Ptf1a- and Ascl1-deficient mice reveals new markers for distinct dorsal horn interneuron populations contributing to nociceptive reflex plasticity.","date":"2013","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/23616538","citation_count":40,"is_preprint":false},{"pmid":"28092367","id":"PMC_28092367","title":"Molecular architecture and dynamics of ASH1 mRNA recognition by its mRNA-transport complex.","date":"2017","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/28092367","citation_count":40,"is_preprint":false},{"pmid":"11948117","id":"PMC_11948117","title":"Quantitative reverse transcription-polymerase chain reaction measurement of HASH1 (ASCL1), a marker for small cell lung carcinomas with neuroendocrine features.","date":"2002","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/11948117","citation_count":40,"is_preprint":false},{"pmid":"18311112","id":"PMC_18311112","title":"Human ASH1 expression in prostate cancer with neuroendocrine differentiation.","date":"2008","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/18311112","citation_count":40,"is_preprint":false},{"pmid":"33577795","id":"PMC_33577795","title":"Molecular Mechanisms Underlying Ascl1-Mediated Astrocyte-to-Neuron Conversion.","date":"2021","source":"Stem cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/33577795","citation_count":38,"is_preprint":false},{"pmid":"10656681","id":"PMC_10656681","title":"Self-association of the SET domains of human ALL-1 and of Drosophila TRITHORAX and ASH1 proteins.","date":"2000","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10656681","citation_count":38,"is_preprint":false},{"pmid":"20457760","id":"PMC_20457760","title":"Multiple Myo4 motors enhance ASH1 mRNA transport in Saccharomyces cerevisiae.","date":"2010","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/20457760","citation_count":38,"is_preprint":false},{"pmid":"23580551","id":"PMC_23580551","title":"Quantitative in vivo analysis of chromatin binding of Polycomb and Trithorax group proteins reveals retention of ASH1 on mitotic chromatin.","date":"2013","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/23580551","citation_count":38,"is_preprint":false},{"pmid":"32573857","id":"PMC_32573857","title":"ASCL1 regulates neurodevelopmental transcription factors and cell cycle genes in brain tumors of glioma mouse models.","date":"2020","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/32573857","citation_count":37,"is_preprint":false},{"pmid":"35263037","id":"PMC_35263037","title":"Promoters of ASCL1- and NEUROD1-dependent genes are specific targets of lurbinectedin in SCLC cells.","date":"2022","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35263037","citation_count":35,"is_preprint":false},{"pmid":"24934812","id":"PMC_24934812","title":"EWS-WT1 oncoprotein activates neuronal reprogramming factor ASCL1 and promotes neural differentiation.","date":"2014","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/24934812","citation_count":35,"is_preprint":false},{"pmid":"32788677","id":"PMC_32788677","title":"Developmental changes in the accessible chromatin, transcriptome and Ascl1-binding correlate with the loss in Müller Glial regenerative potential.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32788677","citation_count":35,"is_preprint":false},{"pmid":"14561888","id":"PMC_14561888","title":"RNA-protein interactions promote asymmetric sorting of the ASH1 mRNA ribonucleoprotein complex.","date":"2003","source":"RNA (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/14561888","citation_count":34,"is_preprint":false},{"pmid":"30771509","id":"PMC_30771509","title":"Ascl1 Regulates Electric Field-Induced Neuronal Differentiation Through PI3K/Akt Pathway.","date":"2019","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/30771509","citation_count":34,"is_preprint":false},{"pmid":"12446785","id":"PMC_12446785","title":"Ash1 protein, an asymmetrically localized transcriptional regulator, controls filamentous growth and virulence of Candida albicans.","date":"2002","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12446785","citation_count":34,"is_preprint":false},{"pmid":"21441980","id":"PMC_21441980","title":"Phorbol-Ester Mediated Suppression of hASH1 Synthesis: Multiple Ways to Keep the Level Down.","date":"2011","source":"Frontiers in molecular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/21441980","citation_count":33,"is_preprint":false},{"pmid":"36206732","id":"PMC_36206732","title":"Cross-lineage potential of Ascl1 uncovered by comparing diverse reprogramming regulatomes.","date":"2022","source":"Cell stem cell","url":"https://pubmed.ncbi.nlm.nih.gov/36206732","citation_count":32,"is_preprint":false},{"pmid":"34558659","id":"PMC_34558659","title":"Performance of DNA methylation analysis of ASCL1, LHX8, ST6GALNAC5, GHSR, ZIC1 and SST for the triage of HPV-positive women: Results from a Dutch primary HPV-based screening cohort.","date":"2021","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34558659","citation_count":31,"is_preprint":false},{"pmid":"34289357","id":"PMC_34289357","title":"Heterogeneity of neurons reprogrammed from spinal cord astrocytes by the proneural factors Ascl1 and Neurogenin2.","date":"2021","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/34289357","citation_count":29,"is_preprint":false},{"pmid":"21684625","id":"PMC_21684625","title":"Insights into the achaete-scute homolog-1 gene (hASH1) in normal and neoplastic human lung.","date":"2012","source":"Lung cancer (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/21684625","citation_count":29,"is_preprint":false},{"pmid":"35149717","id":"PMC_35149717","title":"ASCL1 phosphorylation and ID2 upregulation are roadblocks to glioblastoma stem cell differentiation.","date":"2022","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/35149717","citation_count":28,"is_preprint":false},{"pmid":"34712921","id":"PMC_34712921","title":"MAPK pathway activation selectively inhibits ASCL1-driven small cell lung cancer.","date":"2021","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/34712921","citation_count":28,"is_preprint":false},{"pmid":"23442797","id":"PMC_23442797","title":"The BET protein FSH functionally interacts with ASH1 to orchestrate global gene activity in Drosophila.","date":"2013","source":"Genome biology","url":"https://pubmed.ncbi.nlm.nih.gov/23442797","citation_count":28,"is_preprint":false},{"pmid":"29545540","id":"PMC_29545540","title":"Subcellular localisation modulates ubiquitylation and degradation of Ascl1.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29545540","citation_count":28,"is_preprint":false},{"pmid":"20124469","id":"PMC_20124469","title":"ASCL1 regulates the expression of the CHRNA5/A3/B4 lung cancer susceptibility locus.","date":"2010","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/20124469","citation_count":28,"is_preprint":false},{"pmid":"30121393","id":"PMC_30121393","title":"An Integrative Analysis of Transcriptome and Epigenome Features of ASCL1-Positive Lung Adenocarcinomas.","date":"2018","source":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30121393","citation_count":27,"is_preprint":false},{"pmid":"35194152","id":"PMC_35194152","title":"Therapeutic targeting of BAP1/ASXL3 sub-complex in ASCL1-dependent small cell lung cancer.","date":"2022","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/35194152","citation_count":26,"is_preprint":false},{"pmid":"21036941","id":"PMC_21036941","title":"A nucleoporin, Nup60p, affects the nuclear and cytoplasmic localization of ASH1 mRNA in S. cerevisiae.","date":"2010","source":"RNA (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/21036941","citation_count":26,"is_preprint":false},{"pmid":"39264686","id":"PMC_39264686","title":"Neuroendocrine Differentiation in Prostate Cancer Requires ASCL1.","date":"2024","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/39264686","citation_count":25,"is_preprint":false},{"pmid":"38359163","id":"PMC_38359163","title":"ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts.","date":"2024","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/38359163","citation_count":25,"is_preprint":false},{"pmid":"24324176","id":"PMC_24324176","title":"Role of Loc1p in assembly and reorganization of nuclear ASH1 messenger ribonucleoprotein particles in yeast.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/24324176","citation_count":24,"is_preprint":false},{"pmid":"39609428","id":"PMC_39609428","title":"Transcription factors ASCL1 and OLIG2 drive glioblastoma initiation and co-regulate tumor cell types and migration.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39609428","citation_count":23,"is_preprint":false},{"pmid":"25482892","id":"PMC_25482892","title":"Of social molecules: The interactive assembly of ASH1 mRNA-transport complexes in yeast.","date":"2014","source":"RNA biology","url":"https://pubmed.ncbi.nlm.nih.gov/25482892","citation_count":23,"is_preprint":false},{"pmid":"11195458","id":"PMC_11195458","title":"Morphometric analysis of CC10-hASH1 transgenic mouse lung: a model for bronchiolization of alveoli and neuroendocrine carcinoma.","date":"2000","source":"Experimental lung research","url":"https://pubmed.ncbi.nlm.nih.gov/11195458","citation_count":23,"is_preprint":false},{"pmid":"31212628","id":"PMC_31212628","title":"Inhibition of Glioma Development by ASCL1-Mediated Direct Neuronal Reprogramming.","date":"2019","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/31212628","citation_count":23,"is_preprint":false},{"pmid":"16021468","id":"PMC_16021468","title":"Genetic association analyses of PHOX2B and ASCL1 in neuropsychiatric disorders: evidence for association of ASCL1 with Parkinson's disease.","date":"2005","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16021468","citation_count":22,"is_preprint":false},{"pmid":"32122989","id":"PMC_32122989","title":"Physical interactions between Gsx2 and Ascl1 balance progenitor expansion versus neurogenesis in the mouse lateral ganglionic eminence.","date":"2020","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/32122989","citation_count":22,"is_preprint":false},{"pmid":"29510143","id":"PMC_29510143","title":"Instructing neuronal identity during CNS development and astroglial-lineage reprogramming: Roles of NEUROG2 and ASCL1.","date":"2018","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/29510143","citation_count":21,"is_preprint":false},{"pmid":"36263020","id":"PMC_36263020","title":"The proneural transcription factor ASCL1 regulates cell proliferation and primes for differentiation in neuroblastoma.","date":"2022","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/36263020","citation_count":21,"is_preprint":false},{"pmid":"15272537","id":"PMC_15272537","title":"Human achaete-scute homologue (hASH1) mRNA level as a diagnostic marker to distinguish esthesioneuroblastoma from poorly differentiated tumors arising in the sinonasal tract.","date":"2004","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/15272537","citation_count":21,"is_preprint":false},{"pmid":"35538066","id":"PMC_35538066","title":"Helicobacter pylori infection activates Wnt/β-catenin pathway to promote the occurrence of gastritis by upregulating ASCL1 and AQP5.","date":"2022","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/35538066","citation_count":21,"is_preprint":false},{"pmid":"23481413","id":"PMC_23481413","title":"Heterochronic misexpression of Ascl1 in the Atoh7 retinal cell lineage blocks cell cycle exit.","date":"2013","source":"Molecular and cellular neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/23481413","citation_count":21,"is_preprint":false},{"pmid":"36649415","id":"PMC_36649415","title":"The ASH1-PEX16 regulatory pathway controls peroxisome biogenesis for appressorium-mediated insect infection by a fungal pathogen.","date":"2023","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/36649415","citation_count":20,"is_preprint":false},{"pmid":"35789143","id":"PMC_35789143","title":"ASCL1 regulates super-enhancer-associated miRNAs to define molecular subtypes of small cell lung cancer.","date":"2022","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/35789143","citation_count":20,"is_preprint":false},{"pmid":"35590427","id":"PMC_35590427","title":"Histone H3.3 K27M chromatin functions implicate a network of neurodevelopmental factors including ASCL1 and NEUROD1 in DIPG.","date":"2022","source":"Epigenetics & chromatin","url":"https://pubmed.ncbi.nlm.nih.gov/35590427","citation_count":20,"is_preprint":false},{"pmid":"29683222","id":"PMC_29683222","title":"ASCL1 regulates proliferation of NG2-glia in the embryonic and adult spinal cord.","date":"2018","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/29683222","citation_count":19,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":47153,"output_tokens":7887,"usd":0.129882},"stage2":{"model":"claude-opus-4-6","input_tokens":11639,"output_tokens":3984,"usd":0.236693},"total_usd":0.366575,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2016,\n      \"finding\": \"ASCL1 binds distinct genomic loci and regulates mostly distinct genes compared to NEUROD1 in SCLC; ASCL1 targets oncogenic genes including MYCL1, RET, SOX2, NFIB, and multiple NOTCH pathway genes including DLL3, and is required in vivo for tumor formation in mouse models of SCLC.\",\n      \"method\": \"ChIP-seq, RNA-seq, mouse genetic models (SCLC), shRNA knockdown in human SCLC cell lines\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-seq binding data combined with in vivo mouse genetic requirement, replicated across human and mouse models\",\n      \"pmids\": [\"27452466\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ASCL1 functions as a pioneer transcription factor in glioblastoma stem cells, opening closed chromatin regions to activate a neurogenic gene expression program, promoting terminal neuronal differentiation and suppressing tumorigenicity.\",\n      \"method\": \"ATAC-seq, ChIP-seq, lentiviral ASCL1 overexpression, Notch inhibition in patient-derived glioblastoma stem cells, in vivo tumor assays\",\n      \"journal\": \"Cell stem cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal chromatin and functional assays in patient-derived cells with in vivo validation\",\n      \"pmids\": [\"28712938\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ASCL1 and Neurogenin2 (Neurog2) induce different neuronal fates by binding largely different genomic sites; divergent binding patterns are determined by enrichment of specific E-box sequences reflecting DNA-binding domain preferences, not prior chromatin state, leading to distinct chromatin accessibility and enhancer activity profiles.\",\n      \"method\": \"ChIP-seq, ATAC-seq, direct neuronal programming of embryonic stem cells, E-box motif analysis\",\n      \"journal\": \"Nature neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal chromatin profiling methods with mechanistic mutagenesis-level dissection of binding specificity\",\n      \"pmids\": [\"31086315\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"FOXO3 shares common genomic targets with ASCL1 in adult neural progenitor cells, co-occupying enhancers of neurogenic pathway genes; FOXO3 inhibits ASCL1-dependent neurogenesis in neural progenitor cells and direct neuronal conversion in fibroblasts, and restrains neurogenesis in vivo.\",\n      \"method\": \"ChIP-seq (FOXO3 and ASCL1), ATAC-seq/chromatin landscape analysis, loss-of-function in NPCs and fibroblasts, in vivo neurogenesis assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal genome-wide occupancy data combined with functional loss-of-function in multiple contexts including in vivo\",\n      \"pmids\": [\"23891001\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"ASCL1 (ASH1) transcriptionally activates miR-375 in neuroendocrine lung cancer cells; miR-375 is a downstream effector required for ASH1-mediated induction of neuroendocrine features, and miR-375 directly targets YAP1 to relieve YAP1-mediated growth inhibition.\",\n      \"method\": \"shRNA knockdown of ASH1, miR-375 overexpression/knockdown, luciferase reporter assays, western blotting in lung cancer cell lines\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — functional pathway dissection with knockdown and reporter assays in cell lines, single lab\",\n      \"pmids\": [\"21856745\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"hASH1 stimulates lung cancer cell migration through a Cdk5/p35 pathway; p35 is a direct transcriptional target of hASH1, and hASH1 expression increases p35/Cdk5 activity to enhance cellular migration.\",\n      \"method\": \"shRNA knockdown of hASH1, dominant-negative Cdk5 expression, Cdk5 inhibitor roscovitine, hASH1 overexpression in adenocarcinoma cells, ChIP for p35 promoter\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — direct transcriptional target validation with ChIP and functional phenotypic rescue, single lab\",\n      \"pmids\": [\"22696682\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ASCL1 regulates expression of the CHRNA5/A3/B4 nicotinic acetylcholine receptor gene cluster in small cell lung cancer; ASCL1 knockdown specifically reduced alpha3 and beta4 subunit expression without affecting other nAChR genes, indicating ASCL1-specific transcriptional regulation of this locus.\",\n      \"method\": \"shRNA knockdown of ASCL1 in SCLC and non-SCLC cell lines, qRT-PCR, in silico promoter analysis for ASCL1 binding sites\",\n      \"journal\": \"Molecular cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — specific knockdown phenotype with gene expression readout but no direct binding confirmation by ChIP\",\n      \"pmids\": [\"20124469\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"In adult mouse neural stem cells, oscillatory Hes1 expression drives cyclic Ascl1 expression to promote active proliferation; high sustained Hes1 expression continuously suppresses Ascl1 and promotes quiescence. Inactivation of Hes1 and related genes upregulates Ascl1 and increases neurogenesis, causing depletion of stem cells, while induction of Ascl1 oscillations activates stem cells.\",\n      \"method\": \"Genetic inactivation of Hes1 in mouse, live-cell imaging of Hes1/Ascl1 dynamics, conditional Hes1 overexpression, Ascl1 induction in adult mouse brain\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis combined with live-cell dynamics imaging, multiple orthogonal approaches in vivo\",\n      \"pmids\": [\"30862661\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ASCL1 in SCLC cooperates with NKX2-1 and PROX1 to form complexes that co-regulate genes in NOTCH signaling, catecholamine biosynthesis, and cell-cycle processes; ASCL1 is a key dependency factor in SCLC preclinical models and directly regulates multiple essential genes.\",\n      \"method\": \"ChIP-seq, RNA-seq, super-enhancer mapping, ASCL1 depletion in SCLC models, co-immunoprecipitation\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP for complex formation combined with genome-wide binding and transcriptome analysis\",\n      \"pmids\": [\"34466783\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Ascl1/Mash1 promotes oligodendrocyte precursor cell specification from subventricular zone progenitors and regulates the balance between OPC differentiation and proliferation in postnatal cortex; Ascl1 is required for proper remyelination, with remyelinating oligodendrocytes derived from Ascl1+ progenitors.\",\n      \"method\": \"Conditional genetic deletion of Ascl1 in cortical progenitors or OPCs, mouse focal demyelination model, lineage tracing, immunohistochemistry\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO with defined cellular phenotype and lineage tracing in vivo\",\n      \"pmids\": [\"23739972\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ASCL1 acts as a driver of neuroendocrine/neuronal lineage transcriptional programs in prostate cancer through large-scale chromatin remodeling; ASCL1 motif is enriched in hyper-accessible regions after androgen receptor pathway inhibitor treatment, and targeting ASCL1 switches neuroendocrine lineage back to luminal epithelial state via disruption of PRC2 through UHRF1/AMPK axis.\",\n      \"method\": \"ATAC-seq, ChIP-seq, ASCL1 knockdown, UHRF1/AMPK pathway inhibition, chromatin architecture analysis in prostate cancer cells\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple chromatin profiling methods with mechanistic pathway dissection and phenotypic reversal\",\n      \"pmids\": [\"35477723\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"EZH2 promotes SCLC progression by epigenetically silencing TβRII expression, suppressing TGF-β signaling; ASCL1 is a Smad-dependent TGF-β target gene that promotes survival in SCLC cells, and EZH2 promotes SCLC by suppressing the TGF-β-Smad-ASCL1 pathway.\",\n      \"method\": \"TβRII overexpression in SCLC cells, EZH2 inhibition, Smad pathway activation, in vitro cell growth and in vivo tumor formation assays\",\n      \"journal\": \"Cell discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — pathway dissection with overexpression/knockdown but ASCL1 role as direct Smad target shown by indirect evidence\",\n      \"pmids\": [\"27462425\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"EWS-WT1 fusion oncoprotein directly activates ASCL1 transcription by binding the proximal ASCL1 promoter through multiple WT1-responsive elements, inducing neural gene expression and partial neural differentiation.\",\n      \"method\": \"Transgenic mouse model, ChIP for EWS-WT1 at ASCL1 promoter, reporter assays with WT1-responsive element mutations, EWS-WT1 siRNA knockdown\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct promoter binding confirmed by ChIP with functional rescue, but single lab\",\n      \"pmids\": [\"24934812\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ASCL1 in SCLC represses a SOX9+ mesenchymal/neural crest stem-like state; ASCL1 is critical for expression of NKX2-1, FOXA2, and INSM1 and represses SOX9/RUNX1/RUNX2 program in vivo; genetic depletion of ASCL1 promotes emergence of osteosarcoma and chondroid tumors and inhibits tumor initiation in MYC-driven SCLC.\",\n      \"method\": \"Genetically engineered mouse models with conditional Ascl1 deletion, RNA-seq, ChIP-seq, tumor histology\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic loss-of-function in multiple GEMMs with genome-wide transcriptomic and ChIP analysis\",\n      \"pmids\": [\"34016693\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ASCL1 is a MYCN- and LMO1-dependent member of the adrenergic neuroblastoma core regulatory circuitry; regulatory elements controlling ASCL1 are bound by LMO1, MYCN, GATA3, HAND2, PHOX2B, TBX2 and ISL1; ASCL1 and LMO1 directly regulate CRC gene expression, and ASCL1 is required for neuroblastoma cell growth and arrest of differentiation.\",\n      \"method\": \"ChIP-seq, RNA-seq, ASCL1 knockdown in neuroblastoma cells, promoter/enhancer analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genome-wide ChIP-seq combined with functional knockdown with defined growth and differentiation phenotype\",\n      \"pmids\": [\"31819055\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Endogenous ASCL1 functions both as a classical pioneer factor (binding closed chromatin) and as a non-pioneer remodeler (binding permissive chromatin to induce conformation changes) during human neural differentiation; ASCL1 interacts with BAF SWI/SNF chromatin remodeling complexes, primarily at non-pioneer targets, with codependent DNA binding and remodeling at a subset of ASCL1/SWI/SNF co-targets.\",\n      \"method\": \"Single-cell RNA-seq, ASCL1 knockout model, ATAC-seq, ChIP-seq, Co-IP for ASCL1-SWI/SNF interaction, chromatin conformation assays\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — knockout model defining unbound state combined with multiple chromatin assays and validated protein-protein interaction\",\n      \"pmids\": [\"36931659\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Ascl1-mediated astrocyte-to-neuron conversion directly activates 107 target genes; among direct ASCL1 targets, Klf10 regulates neuritogenesis, Myt1 and Myt1l are critical for electrophysiological maturation of induced neurons, and Neurod4 and Chd7 are required for efficient conversion.\",\n      \"method\": \"RNA-seq, ChIP-seq during astrocyte-to-neuron reprogramming, siRNA knockdown of individual ASCL1 targets, functional electrophysiology assays\",\n      \"journal\": \"Stem cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct ChIP-seq target identification combined with functional siRNA validation of individual targets with specific phenotypic readouts\",\n      \"pmids\": [\"33577795\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ASCL1 is ubiquitylated on lysines within the bHLH domain in the cytoplasm by the E3 ligase Huwe1, targeting it for degradation; chromatin-bound ASCL1 associates with short ubiquitin chains that do not target it for destruction, occurring on lysines in the N-terminal region or bHLH domain independently of Huwe1. Thus subcellular localization controls the type of ubiquitylation and fate of ASCL1.\",\n      \"method\": \"Subcellular fractionation, ubiquitin chain immunoprecipitation, lysine-to-arginine mutagenesis, Huwe1 knockdown, proteasome inhibition experiments\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — reconstitution-level mutagenesis combined with E3 ligase identification and fractionation, multiple orthogonal methods\",\n      \"pmids\": [\"29545540\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ASCL1 is highly phosphorylated on Serine-Proline sites in GBM stem cells; a phosphorylation-resistant form of ASCL1 (cannot be phosphorylated on SP sites) drives GBM cells more efficiently into neuronal lineage and out of cell cycle than wild-type ASCL1; deletion of ID2 further enhances this differentiation block reversal.\",\n      \"method\": \"Phospho-ASCL1 immunoblotting, overexpression of phospho-mutant ASCL1 in GBM stem cells, CRISPR deletion of ID2, cell cycle analysis, differentiation markers\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mutagenesis of phosphorylation sites with functional differentiation/proliferation readout, single lab\",\n      \"pmids\": [\"35149717\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Injury-induced STAT signaling limits Ascl1-mediated reprogramming of Müller glia into retinal neurons; STAT signaling directs Ascl1 to developmentally inappropriate chromatin targets; pharmacological STAT inhibition combined with Ascl1 expression dramatically increases neuronal generation from Müller glia.\",\n      \"method\": \"Single-cell RNA-seq, Ascl1-ChIPseq, ATAC-seq in Müller glia, STAT inhibitor treatment, transgenic Ascl1 expression\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-seq demonstrating STAT-dependent target shifting of ASCL1 with functional consequence, multiple orthogonal methods\",\n      \"pmids\": [\"32075759\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ASCL1 regulates neurodevelopmental transcription factors and cell cycle genes in GBM; genetic loss of ASCL1 significantly reduces glioma cell proliferation in a mouse glioma model, with RNA-seq revealing downregulation of cell cycle genes upon ASCL1 loss.\",\n      \"method\": \"RNA-seq, conditional Ascl1 deletion in mouse glioma model, survival analysis, cell proliferation assays\",\n      \"journal\": \"Glia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO in vivo with transcriptome analysis, but limited mechanistic depth beyond transcriptional targets\",\n      \"pmids\": [\"32573857\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ASCL1 proneural transcription factor governs glioblastoma stem cell proneural subgroup affiliation by directly repressing NDRG1 (a mesenchymal gene); ASCL1 binding to NDRG1 regulatory regions drives a glial-to-neuronal lineage switch while concomitantly suppressing mesenchymal features.\",\n      \"method\": \"ChIP-seq, ASCL1 overexpression/knockdown, NDRG1 silencing, tumor formation assays, gene expression profiling in patient-derived GSCs\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — ChIP-seq with functional validation by knockdown, single lab\",\n      \"pmids\": [\"30538287\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ASCL1 is required for the neuroendocrine lineage transition in prostate cancer; ASCL1+ cells arise from KRT8+ luminal cells in vivo; Ascl1 loss in established NEPC causes transient regression followed by recurrence, but deletion before transplantation abrogates lineage plasticity resulting in castration-sensitive adenocarcinomas.\",\n      \"method\": \"Mouse prostate organoid transplantation model, multiplexed immunofluorescence, spatial transcriptomics, genetic Ascl1 deletion at different tumor stages\",\n      \"journal\": \"Nature cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic model with spatial multi-omics and staged deletion showing temporal dependency\",\n      \"pmids\": [\"39394434\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Ascl1 loss in mouse prostate cancer model does not decrease tumor incidence or growth, but causes notable decrease in neuroendocrine identity and increase in basal-like identity, establishing ASCL1 as required for driving NE differentiation but not overall tumor growth in this context.\",\n      \"method\": \"Prostate organoid allografts from Rb1/Trp53/Myc GEMMs, conditional Ascl1 genetic deletion, IHC/RNA-seq for lineage markers\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean in vivo KO with specific lineage phenotype, single lab\",\n      \"pmids\": [\"39264686\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Gsx2 physically interacts with the bHLH domain of Ascl1 in lateral ganglionic eminence progenitors, interfering with Ascl1's DNA binding and limiting neurogenesis; this Gsx2-Ascl1 interaction is enriched in LGE ventricular zone progenitors, while Ascl1-E-protein (Tcf3) interactions predominate in the subventricular zone.\",\n      \"method\": \"Luciferase/reporter assays, co-immunoprecipitation, DNA-binding assays, proximity ligation assay in tissue sections, conditional misexpression in mouse\",\n      \"journal\": \"Development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct physical interaction validated by co-IP and DNA-binding assays, spatial proximity ligation in tissue with functional luciferase readout\",\n      \"pmids\": [\"32122989\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ASCL1 in SCLC regulates super-enhancer-associated miRNAs including miR-7, miR-375, miR-200b-3p, and miR-429 (activating them) and suppresses miR-455-3p; multiple ASCL1-regulated miRNAs combinatorially repress targets including YAP1 (co-targeted by miR-9 and miR-375).\",\n      \"method\": \"CUT&Tag chromatin profiling (H3K27me3, H3K4me3, H3K27ac), ASCL1 knockdown with RNA-seq and miRNA array in SCLC cells\",\n      \"journal\": \"Cancer science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — genome-wide chromatin and transcriptome profiling after ASCL1 depletion, single lab\",\n      \"pmids\": [\"35789143\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"The BAP1/ASXL3/BRD4 epigenetic axis regulates ASCL1-dependent SCLC transcriptional programming; pharmacological inhibition of BAP1 catalytic activity induces ASXL3 degradation, disrupting the BAP1/ASXL3/BRD4 complex at active enhancers and repressing ASCL1/MYCL/E2F neuroendocrine lineage signaling.\",\n      \"method\": \"BAP1 inhibitor (iBAP-II) treatment, Co-IP for BAP1/ASXL3/BRD4 complex, ChIP-seq at enhancers, cell viability and in vivo tumor assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — complex shown by Co-IP with chromatin evidence and functional readout, but epigenetic regulation of ASCL1 shown pharmacologically\",\n      \"pmids\": [\"35194152\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Notch1 intracellular domain inhibits differentiation of neuroblastoma cells; HES1 binds to an N-box sequence in the HASH-1 (ASCL1) promoter in gel mobility shift assays, and HES1 activation during differentiation contributes to HASH-1 downregulation.\",\n      \"method\": \"Gel mobility shift assay with HES1 protein and ASCL1 N-box oligonucleotide, constitutive Notch1-ICD expression, differentiation assays in neuroblastoma cell lines\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — direct binding of HES1 to ASCL1 promoter element confirmed by EMSA, with functional differentiation phenotype\",\n      \"pmids\": [\"11054669\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ASCL1 conditional deletion in NG2-glia of embryonic or adult spinal cord results in significant reduction in proliferation but not differentiation of these cells; WM NG2-glia maintain higher ASCL1 levels than GM NG2-glia, correlating with higher proliferative capacity; ASCL1+ OLP clones are primarily restricted to GM or WM compartments.\",\n      \"method\": \"Conditional Ascl1 deletion in NG2-glia, long-term clonal lineage analysis, BrdU/EdU proliferation assays in spinal cord\",\n      \"journal\": \"Glia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO with specific cellular proliferation phenotype distinguished from differentiation, in vivo\",\n      \"pmids\": [\"29683222\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"In neuroblastoma, ASCL1 maintains rapid proliferation and regulates chromatin accessibility at differentiation gene regulatory regions; ASCL1 deletion compromises the ability of MYC/MYCN and CRC component proteins PHOX2B and GATA3 to bind chromatin, without substantially affecting CRC gene transcript levels.\",\n      \"method\": \"CRISPR deletion of ASCL1 in neuroblastoma cell lines, genome-wide RNA-seq, ATAC-seq, ChIP-seq for PHOX2B/GATA3 binding, proliferation assays\",\n      \"journal\": \"Frontiers in cell and developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal genomic methods with CRISPR KO, single lab\",\n      \"pmids\": [\"36263020\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Ascl1, together with Mef2c, drives efficient cardiac reprogramming; MEF2C shifts ASCL1 chromatin binding away from neuronal gene targets toward cardiac gene targets, demonstrating cross-lineage pioneer factor activity dependent on partner transcription factor context.\",\n      \"method\": \"ChIP-seq, RNA-seq during cardiac reprogramming, MEF2C co-expression with ASCL1, comparison to neuronal reprogramming regulatome\",\n      \"journal\": \"Cell stem cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genome-wide binding shift shown by ChIP-seq with functional cardiac reprogramming outcome, single lab\",\n      \"pmids\": [\"36206732\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Loss of Ascl1 in mouse dorsal horn specifically eliminates late-born inhibitory interneurons; Ascl1-dependent inhibitory interneurons expressing pDyn, Kcnip2, and Rorb are key players in nociceptive reflex plasticity.\",\n      \"method\": \"Genome-wide expression profiling of Ascl1-/- spinal dorsal horn, in situ hybridization, isolated spinal cord electrophysiology for nociceptive reflex\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with defined neuronal population loss and functional electrophysiology\",\n      \"pmids\": [\"23616538\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ASCL1 drives drug tolerance to osimertinib in EGFR-mutant lung cancer by initiating an epithelial-to-mesenchymal gene expression program in permissive cellular contexts.\",\n      \"method\": \"Patient-derived xenograft osimertinib treatment, single-cell transcriptional profiling of residual disease, ASCL1 expression analysis\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — transcriptional profiling with mechanistic inference, limited functional validation of ASCL1 as causative driver\",\n      \"pmids\": [\"38359163\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ASCL1 is a bHLH proneural transcription factor and pioneer factor that binds specific E-box sequences to open closed chromatin and activate neurogenic/neuroendocrine gene expression programs; it cooperates with chromatin remodeling complexes (BAF/SWI/SNF) and partner transcription factors (NKX2-1, PROX1, MEF2C) to regulate distinct genomic targets, and its activity is modulated post-translationally by phosphorylation on SP sites (which promotes proliferation over differentiation) and by context-dependent ubiquitylation through Huwe1 (cytoplasmic, leading to degradation) or short non-degradative ubiquitin chains on chromatin; in neural and neuroendocrine development it acts downstream of Notch/Hes1 repression and upstream of multiple lineage-specifying targets including miRNAs, driving both progenitor proliferation and differentiation in a dose/oscillation-dependent manner, while also being required for neuroendocrine lineage identity in lung and prostate cancers.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"ASCL1 is a basic helix-loop-helix (bHLH) proneural transcription factor that functions as a pioneer factor, binding specific E-box sequences to open closed chromatin and activate neuronal and neuroendocrine gene expression programs across diverse cellular contexts [PMID:28712938, PMID:31086315, PMID:36931659]. ASCL1 cooperates with BAF/SWI-SNF chromatin remodeling complexes at permissive chromatin sites and with lineage-specifying partner transcription factors—including NKX2-1/PROX1 in small cell lung cancer, PHOX2B/GATA3 in neuroblastoma, and MEF2C in cardiac reprogramming—that redirect its genomic binding from neuronal to alternative lineage targets [PMID:36931659, PMID:34466783, PMID:36263020, PMID:36206732]. Its activity is tuned by oscillatory expression dynamics downstream of Notch/Hes1 signaling, by serine-proline phosphorylation that favors proliferation over differentiation, and by subcellular-compartment-specific ubiquitylation wherein cytoplasmic Huwe1-mediated ubiquitylation drives degradation while chromatin-associated short ubiquitin chains preserve ASCL1 function [PMID:30862661, PMID:35149717, PMID:29545540]. ASCL1 is required for neuroendocrine lineage identity and tumor initiation in small cell lung cancer and neuroendocrine prostate cancer, where its loss abolishes neuroendocrine differentiation and shifts cells toward alternative lineage states [PMID:27452466, PMID:39394434, PMID:34016693].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Establishing that ASCL1 transcription is directly repressed by HES1 through N-box binding placed ASCL1 downstream of Notch signaling, answering how Notch activation suppresses neuronal differentiation at the promoter level.\",\n      \"evidence\": \"EMSA showing HES1 binding to ASCL1 promoter N-box, Notch1-ICD overexpression in neuroblastoma cells\",\n      \"pmids\": [\"11054669\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No ChIP confirmation of HES1 occupancy at endogenous ASCL1 promoter in vivo\", \"Kinetics of HES1-mediated repression not resolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identification of miR-375 as a direct ASCL1 transcriptional target that represses YAP1 revealed a non-coding RNA effector arm through which ASCL1 promotes neuroendocrine features in lung cancer.\",\n      \"evidence\": \"shRNA knockdown of ASCL1, miR-375 manipulation, luciferase reporter assays in NE lung cancer lines\",\n      \"pmids\": [\"21856745\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct ASCL1 binding to miR-375 regulatory region not shown by ChIP at this stage\", \"Contribution of miR-375 relative to other ASCL1 targets unclear\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Conditional deletion studies demonstrated that ASCL1 is required not only for neuronal specification (inhibitory dorsal horn interneurons) but also for oligodendrocyte precursor cell specification and remyelination, broadening its known lineage roles beyond neurons.\",\n      \"evidence\": \"Conditional Ascl1 KO in cortical/OPC progenitors and spinal dorsal horn, lineage tracing, demyelination model\",\n      \"pmids\": [\"23739972\", \"23616538\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets mediating OPC vs. neuronal specification not distinguished\", \"Whether ASCL1 binding sites differ in OPC vs. neuronal progenitors was unknown\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Demonstration that FOXO3 co-occupies ASCL1-bound enhancers and antagonizes ASCL1-dependent neurogenesis established a paradigm for how signaling pathways modulate ASCL1 pioneer activity through co-factor competition at shared genomic targets.\",\n      \"evidence\": \"ChIP-seq for FOXO3 and ASCL1 in neural progenitor cells, loss-of-function in NPCs/fibroblasts, in vivo neurogenesis\",\n      \"pmids\": [\"23891001\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism of FOXO3 antagonism (competition vs. active repression) not resolved\", \"Whether FOXO3 blocks ASCL1 chromatin opening specifically was untested\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Genome-wide ChIP-seq in SCLC revealed that ASCL1 and NEUROD1 define distinct transcriptional subgroups by binding largely non-overlapping genomic sites, establishing ASCL1 as a master regulator of a specific SCLC oncogenic program including MYCL1, RET, and DLL3.\",\n      \"evidence\": \"ChIP-seq and RNA-seq in human SCLC lines, shRNA knockdown, mouse SCLC GEMMs\",\n      \"pmids\": [\"27452466\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How ASCL1 vs. NEUROD1 binding specificity is determined at the DNA/protein level was unknown\", \"Whether ASCL1 acts as a pioneer factor in SCLC was not yet addressed\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"ATAC-seq and ChIP-seq in glioblastoma stem cells provided the first direct evidence that ASCL1 functions as a pioneer factor, opening previously closed chromatin to activate a neurogenic differentiation program and suppress tumorigenicity.\",\n      \"evidence\": \"ATAC-seq/ChIP-seq after lentiviral ASCL1 expression in patient-derived GBM stem cells, in vivo tumor assays\",\n      \"pmids\": [\"28712938\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether pioneer activity requires cofactors or is intrinsic to ASCL1 was not dissected\", \"Mechanism of chromatin opening (nucleosome displacement vs. remodeler recruitment) unresolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Biochemical dissection of ASCL1 ubiquitylation revealed that subcellular location dictates its post-translational fate: cytoplasmic Huwe1-mediated ubiquitylation on bHLH-domain lysines drives degradation, while chromatin-bound ASCL1 carries short non-degradative ubiquitin chains on distinct residues.\",\n      \"evidence\": \"Subcellular fractionation, ubiquitin IP, lysine-to-arginine mutagenesis, Huwe1 knockdown\",\n      \"pmids\": [\"29545540\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Function of non-degradative chromatin-associated ubiquitin chains unknown\", \"E3 ligase responsible for chromatin-associated ubiquitylation not identified\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Comparison of ASCL1 and Neurog2 binding in ES cell-derived neurons showed that divergent neuronal fates arise from intrinsic E-box sequence preferences of the bHLH DNA-binding domains rather than from prior chromatin states, resolving how two pioneer factors accessing closed chromatin produce distinct outcomes.\",\n      \"evidence\": \"ChIP-seq, ATAC-seq, E-box motif analysis during directed neuronal programming from ESCs\",\n      \"pmids\": [\"31086315\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for differential E-box recognition not determined\", \"Whether cofactor interactions modulate E-box selectivity in vivo untested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Live imaging of Hes1/Ascl1 oscillatory dynamics in adult neural stem cells demonstrated that oscillatory (low-amplitude) Ascl1 expression maintains proliferative capacity while sustained high expression drives differentiation, establishing expression dynamics as a functional switch.\",\n      \"evidence\": \"Live-cell imaging, conditional Hes1 genetic manipulation, Ascl1 induction in adult mouse brain\",\n      \"pmids\": [\"30862661\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How oscillatory vs. sustained ASCL1 protein levels differentially engage target genes mechanistically was unresolved\", \"Post-translational regulation during oscillations not examined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"STAT signaling in injured Müller glia was shown to redirect Ascl1 binding to developmentally inappropriate chromatin targets, establishing that the signaling environment can reprogram pioneer factor genomic occupancy and limit regenerative neurogenesis.\",\n      \"evidence\": \"Ascl1 ChIP-seq ± STAT inhibition in Müller glia, single-cell RNA-seq, ATAC-seq\",\n      \"pmids\": [\"32075759\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether STAT factors physically interact with ASCL1 or act indirectly via chromatin remodeling unknown\", \"Generalizability to other injury contexts not tested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identification of ASCL1 cooperation with NKX2-1 and PROX1 as co-occupying transcription factors at super-enhancers in SCLC, combined with in vivo demonstration that ASCL1 loss derepresses a SOX9+ mesenchymal program while being required for NE identity, defined ASCL1 as both an activator of NE lineage and a repressor of alternative fates.\",\n      \"evidence\": \"ChIP-seq, Co-IP for ASCL1/NKX2-1/PROX1, conditional Ascl1 deletion in SCLC GEMMs, RNA-seq\",\n      \"pmids\": [\"34466783\", \"34016693\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and assembly order of ASCL1/NKX2-1/PROX1 complex unknown\", \"Whether ASCL1 actively recruits repressive machinery to SOX9 loci or acts indirectly unclear\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"ASCL1 was established as a driver of neuroendocrine lineage plasticity in prostate cancer through chromatin remodeling involving a PRC2/UHRF1/AMPK axis, and partner-dependent redirection of ASCL1 binding by MEF2C toward cardiac genes demonstrated that ASCL1 pioneer activity is fundamentally context-dependent.\",\n      \"evidence\": \"ATAC-seq/ChIP-seq in prostate cancer with ASCL1 knockdown and UHRF1/AMPK pathway perturbation; ChIP-seq during ASCL1+MEF2C cardiac reprogramming\",\n      \"pmids\": [\"35477723\", \"36206732\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct physical interaction between ASCL1 and PRC2 components not shown\", \"How MEF2C mechanistically redirects ASCL1 DNA binding unclear\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Endogenous ASCL1 knockout during human neural differentiation combined with SWI/SNF interaction studies revealed a dual mode: classical pioneer activity at closed chromatin and non-pioneer remodeling at permissive chromatin via BAF complex recruitment, resolving how ASCL1 engages chromatin through two mechanistically distinct pathways.\",\n      \"evidence\": \"ASCL1 KO hESC differentiation model, ATAC-seq, ChIP-seq, Co-IP for ASCL1-SWI/SNF\",\n      \"pmids\": [\"36931659\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which BAF complex subunits directly contact ASCL1 not mapped\", \"Whether pioneer vs. non-pioneer mode distinction applies in cancer contexts unknown\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Staged genetic deletion in prostate cancer models showed ASCL1 is required for initiating the neuroendocrine lineage transition from luminal cells but becomes partially dispensable in established tumors, revealing a temporal hierarchy in ASCL1 dependency for lineage plasticity.\",\n      \"evidence\": \"Mouse organoid transplantation with conditional Ascl1 deletion at different stages, spatial transcriptomics, multiplexed IF\",\n      \"pmids\": [\"39394434\", \"39264686\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Compensatory factors maintaining NE identity after ASCL1 loss in established tumors not identified\", \"Whether ASCL1 re-expression drives re-emergence of NE phenotype untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis for ASCL1's differential E-box selectivity, the identity and function of the E3 ligase responsible for non-degradative chromatin-associated ubiquitylation, and how oscillatory vs. sustained ASCL1 expression differentially engages downstream targets at the molecular level.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural model of ASCL1 DNA-binding domain bound to preferred E-box variants\", \"E3 ligase for chromatin-associated non-degradative ubiquitylation unknown\", \"Molecular mechanism linking ASCL1 protein oscillation amplitude to target gene selection unresolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 1, 2, 3, 15, 16, 24]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 1, 4, 8, 10, 13, 14, 16, 25]},\n      {\"term_id\": \"GO:0042393\", \"supporting_discovery_ids\": [15]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 1, 2, 15, 17]},\n      {\"term_id\": \"GO:0005694\", \"supporting_discovery_ids\": [15, 17]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [17]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 1, 2, 4, 8, 10, 13, 14, 15, 16, 25]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [1, 2, 10, 15, 29]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [7, 9, 19, 24, 31]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [7, 11, 27]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [8, 18, 20, 29]}\n    ],\n    \"complexes\": [\n      \"BAF/SWI-SNF complex\"\n    ],\n    \"partners\": [\n      \"NKX2-1\",\n      \"PROX1\",\n      \"MEF2C\",\n      \"HUWE1\",\n      \"GSX2\",\n      \"FOXO3\",\n      \"HES1\",\n      \"TCF3\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}